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Abstract
Background: Cancer research to date has largely focused on somatically acquired genetic aberrations. In contrast,
the degree to which germline, or inherited, variation contributes to tumorigenesis remains unclear, possibly due to
a lack of accessible germline variant data. Here we called germline variants on 9618 cases from The Cancer Genome
Atlas (TCGA) database representing 31 cancer types.
Results: We identified batch effects affecting loss of function (LOF) variant calls that can be traced back to differences
in the way the sequence data were generated both within and across cancer types. Overall, LOF indel calls were more
sensitive to technical artifacts than LOF Single Nucleotide Variant (SNV) calls. In particular, whole genome amplification
of DNA prior to sequencing led to an artificially increased burden of LOF indel calls, which confounded association
analyses relating germline variants to tumor type despite stringent indel filtering strategies. The samples affected by
these technical artifacts include all acute myeloid leukemia and practically all ovarian cancer samples.
Conclusions: We demonstrate how technical artifacts induced by whole genome amplification of DNA can lead to
false positive germline-tumor type associations and suggest TCGA whole genome amplified samples be used with
caution. This study draws attention to the need to be sensitive to problems associated with a lack of uniformity in data
generation in TCGA data.
Keywords: Cancer genomics, TCGA, Cancer germline, Whole exome sequencing, Variant calling, GATK, Batch effects,
Whole genome amplification, Variant annotation, Genetic association testing
Background
Cancer research to date has largely focused on genetic
aberrations that occur specifically in tumor tissue. This
is not without reason as tumor formation is driven to a
great degree by somatically-acquired changes [1]. How-
ever, the degree to which germline, or inherited, DNA
variants contribute to tumorigenesis is unknown. While
it has been clearly demonstrated that germline variation
increases cancer risk in overt and rare familial cancer
predisposition syndromes, the contribution of germline
variation to more common and sporadic cancer risk is
unclear and highly debated [1, 2]. It is likely that inherited
germline variation in fundamental molecular processes,
such as DNA repair, can create a more permissive
environment for tumorigenesis and shape tumor growth
in some individuals [3–5]. It is also likely that variation in
the host germline genome can act synergistically with ac-
quired somatic mutations to shape the way in which tu-
mors grow and ultimately manifest.
There is a growing interest in better understanding the
contribution of germline variation to cancer risk and
tumor phenotypes [6, 7]. The most extensive pan-cancer
germline study to date identified associations between
deleterious germline variation in known cancer predis-
posing genes and both age of onset and somatic muta-
tion burden [6]. Lu et. al demonstrated that inherited
variants can increase risk of developing cancer, as well as
influence tumor growth and overall phenotypic features.
Similar results were found in a study of bialleleic mismatch
repair deficiency (bMMRD). It is known that bMMRD
predisposes to childhood cancer, but it was further demon-
strated that acquisition of somatic mutations in polymerase
genes (POLE, POLD1) led to a hypermutated phenotype in
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childhood brain tumors [8]. This demonstrates a synergis-
tic interaction between germline variation and somatic mu-
tation. A comprehensive study of breast cancer whole
genomes identified a somatic copy number profile signa-
ture associated with BRCA1 inactivation [9]. Interestingly,
this profile was associated with either inactivation of
BRCA1 in the tumor via mutation or promoter hyperme-
thylation, or via inherited germline variants. This shows
that somatic mutation and germline variation can both in-
fluence tumor phenotype.
We chose to use the whole exome sequence (WXS)
data from TCGA to investigate the role of germline vari-
ation in shaping tumor phenotypes. TCGA is an attract-
ive dataset for this purpose as there are paired tumor
normal data for many cancer types. We took a pan-
cancer approach for two reasons: 1. increased sample
size and therefore increased power to detect associations
of small effect size; and 2. cancers of disparate origin
may share common features which would be overlooked
in a cancer type-specific analysis [10]. For example,
germline mutations in BRCA1/2 are most commonly
studied in breast and ovarian cancer, but have also been
shown to increase risk for stomach and prostrate cancer
[11]. Further, germline BRCA2 mutations have been as-
sociated with a distinct somatic mutational phenotype
and an overall increased somatic mutation burden in
both prostrate and breast cancer [6, 9, 12]. To our
knowledge, a comprehensive germline analysis of all can-
cer types available in TCGA has not been performed.
Thus other cross-cancer germline associations likely re-
main to be discovered.
In an ideal dataset, a single protocol should be used
for processing all samples. Unfortunately, this is unreal-
istic in large public datasets like TCGA in which samples
are collected over time and across many data centers.
Since its inception in 2005, TCGA has collected data on
11,000 patients from 20 collaborating institutions and
generated sequence data from 3 sequencing centers [13].
Differences in sample collection and processing across
centers could lead to batch effects, or variation in the
data due to a technical factor that masks relevant bio-
logical variation [14]. Problems with batch effects can be
amplified when analyzing samples across TCGA, since the
number of methods used to collect samples increases with
the number of cancer types. The Pan-Cancer Analysis
Project has recognized this and aims to generate a high
quality dataset of 12 TCGA cancer types, taking care to
identify and minimize technical artifacts [10].
While extensive curated somatic data are available
from TCGA, germline information is currently only
available in raw form, under controlled access. There-
fore, we first had to develop and execute a variant calling
pipeline on the raw normal tissue sequence data. As a
main goal of our variant calling analysis is to create a
cohesive, pan-cancer dataset, we chose to use the Gen-
ome Analysis Toolkit (GATK) joint calling approach [15,
16]. Joint calling is a strategy for variant calling in which
read data are shared across samples, in contrast to single
sample calling where genotype decisions are made based
on reads from a single sample only. There are three
major advantages of this approach: the ability to distinguish
sites that are homozygous reference vs. those that have
insufficient data to make a call, increased sensitivity to
detect variant sites that are poorly covered in any individual
sample but well covered when the cohort is considered as a
whole, and the ability to use GATK’s statistical modeling
approach to variation filtration, known as ‘variant quality
score recalibration’ (VQSR).
Here we describe our experience calling germline vari-
ants from a large cohort of TCGA normal tissue WXS
samples spanning 31 cancer types. Specifically, we were
interested in cataloguing sources of heterogeneity in
sample preparation, identifying batch effects in our vari-
ant calls, and determining methods to reduce or control
for technical noise. Our finding reveals a critical artifact
introduced by preparation of DNA samples through
whole genome amplification, leading to false positive
LOF indels. The study therefore highlights the import-
ance of quality control at all stages of the variant calling
process and suggest that pan-cancer analysis with TCGA
data be approached with caution.
Results
Technical heterogeneity in TCGA WXS Data Generation
We obtained TCGA WXS data from CGhub in the form
of reads aligned to the human reference genome (BAM
files) [17]. From the BAM files and available metadata
we identified seven technical sources of variation in the
way the sequence data were generated: tissue source of
normal DNA, exome capture kit, whole genome amplifi-
cation of DNA prior to sequencing (WGA), sequencing
center, sequencing technology, BWA version, and cap-
ture efficiency (C20X) (Additional file 1: Figure S1, Add-
itional file 2). We found substantial variation existed
within and between cancer types with respect to these
technical factors (Fig. 1). Some of these technical factors
were found to be highly associated with cancer type,
such as use of Illumina Genome Analyzer II and ovarian
cancer (OV), while others exhibited no clear relationship
with cancer type, such as use of solid normal tissue as
opposed to blood as a source of normal DNA. Relation-
ships existed between pairs of technical factors as well,
such as the Broad Institute’s exclusive use of a custom
Agilent exome capture kit. All possible combinations of
the first six technical factors produce 1152 unique work-
flows, of which only 44 were used to generate the TCGA
data. This further demonstrates that relationships exist
between technical factors. Of the 31 cancer types
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examined, only uveal melanoma (UVM) and testicular
germ cell tumors (TCGT) had a uniform workflow for
all samples (Additional file 1: Figure S1). These observa-
tions highlight the substantial heterogeneity in data gen-
eration across TCGA and importantly even within
cancer types.
The technical factors can ultimately be divided into
two categories: those that can be modified during pro-
cessing of the sequence data (BWA version, target re-
gions of a capture kit), and those that cannot be
modified computationally (source of normal DNA,
WGA, center, technology, capture efficiency). Six exome
capture kits ranging in size from 33 to 64 MB were used
to capture normal DNA for sequencing (Additional file
1: Table S2). As the goal of our variant calling pipeline
was obtain a uniform set of variants across samples, we
chose to restrict analysis to the intersection of the
capture regions. The area hereby excluded consists
largely of exon flanking regions. The intersection covers
97.7% of Gencode exons, thus for the purposes of study-
ing protein-coding variation using the intersection of the
kits leads to minimal loss of data (Additional file 1: Table
S2) [18]. It has been shown that differences in capture
efficiency and sample preparation protocols between ex-
ome kits can affect variant calls, even in regions com-
mon between kits [19]. Therefore, despite using the
common capture region, the use of multiple capture kits
may still introduce artifacts.
To assess the effect of heterogeneous BWA alignments
on variant calls, we called variants on 345 of the TCGA
normal samples either using the provided BAM (OldA-
lign) or stripping and realigning reads to GRCh37 using
BWA MEM v.0.7.12 (NewAlign). The overall raw dis-
cordance rates between the two sets of variants was 5%,
Fig. 1 Overview of technical covariates for pan-cancer samples. For each covariate and cancer type, color represents the fraction of total samples.
Fraction of total samples sums to 1 for each covariate and cancer type. Red indicates higher heterogeneity. Year first published included for
context. TCGA cancer abbreviations: ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC,
cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal
carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear
cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular
carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic
adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC,
sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; UCEC,
uterine corpus endometrioid carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma
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which is in the expected range for different alignment
protocols (Additional file 1: Figure S3) [20]. Indel calls
were noticeably more discordant, consistent with the
specific challenges and notorious variability of indel call-
ing [21]. Interestingly, the discordance rate was corre-
lated with BWA version used to generate the BAM file
in CGhub, with older versions displaying more discord-
ance. This effect can largely be reduced by applying
VQSR filters, which decreases overall discordance from
5 to 3% (Additional file 1: Figure S4). Greater discord-
ance between variant calling pipelines has been observed
in repetitive regions of the genome, and in accordance
with this we reduce overall discordance to 1.7% with the
removal of repetitive regions from analysis (Additional
file 1: Figure S3) [22]. As no set of true positive variants
exists for TCGA samples, we cannot determine whether
realigning BAM files produces more accurate calls.
Given the computational cost of realignment, and that
discordance can be mitigated by filtering variants and
masking repetitive regions of the genome, we proceeded
with variant calling using the provided BAM files.
Functional annotation of the 1,093,501 variants in the
final VCF predicted 625,365 missense; 371,754 silent;
24,455 nonsense; 2968 splice site; 553 stoploss; 46,280
frameshift indels and 22,126 in-frame indels in 9618
samples. For initial quality control we performed princi-
pal component analysis (PCA) to identify the most sig-
nificant sources of variation in the variant calls. PCA on
common variants showed that the first two principal
components stratified samples by self-reported race and
ethnicity, indicating that the largest source of variation
is ethnic background and not technical factors (Add-
itional file 1: Figure S5). To assess the quality of the
calls, we measured the fraction of variants also present
in the ExAC database [23]. We expect a high degree of
overlap between our calls and ExAC, as the ExAC v0.3.1
dataset includes germline variants from 7601 TCGA in-
dividuals. Overall 88.56% of the variant calls were
present in ExAC, with SNVs showing higher overlap
than indels (89.91% vs. 53.94%). Based on these results,
we concluded the variant calls were free of overt tech-
nical artifacts and proceeded to the next stage of
analysis.
Impact of technical heterogeneity on loss of function
variants
There is great interest in understanding how inherited
impaired functionality of cancer-relevant pathways
shapes tumor phenotypes, as has been previously dem-
onstrated for bMMRD and BRCA1 germline mutations
[6, 8, 9]. To identify germline variation likely to disrupt
function of genes, we used VEP and LOFTEE to predict
LOF variants in this cohort [24]. We observed a median
150 LOF per sample across our entire cohort, consistent
with the ExAC findings (Fig. 2a) [23]. However, two can-
cer types, acute myeloid leukemia (LAML) and OV devi-
ate significantly from this expected value, with individuals
with these cancers having up to 500 LOF germline vari-
ants. This suggests an artifact was manifesting in rare LOF
variants that was not identified by PCA on common vari-
ants. Notably this effect is specific to LOF indels, in con-
trast to LOF SNVs that are distributed more uniformly
across cancer types (Additional file 1: Figure S6).
We used Analysis of Variance (ANOVA) to assess the
contribution of each technical factor to individual LOF
variant burden. Initial analysis showed that source of
normal control DNA and sequencing technology were
not significantly associated with LOF variant burden,
and that capture kit was highly collinear with sequencing
center. Therefore, we limited subsequent analysis to se-
quencing center, BWA version, WGA, and C20X. It is
known that LOF variant burden varies between ethnic
groups, thus we include self-reported race as a covariate
in this analysis as a reference point for expected vari-
ation [23]. All technical factors combined explain less
than 1% of the variance in LOF SNV burden, indicating
SNVs are largely unaffected by technical variation. In
contrast, 59% of variation in LOF indel burden was ex-
plained by technical factors, with WGA alone explaining
over 50% (Table 1).
WGA samples have a higher LOF variant burden with
a median 201 LOF variants per WGA sample. Four can-
cer types contain samples that underwent WGA: colon
adenocarcinoma (COAD) (26% WGA), rectum adeno-
carcinoma (READ) (33% WGA), OV, (92% WGA) and
LAML (100% WGA) (Fig. 1). Analyzing cancer types
containing both amplified and non-amplified DNA sam-
ples, we observed that WGA samples had a significantly
higher LOF variant burden (Fig. 2b), further suggesting
that WGA rather than cancer type is the main source of
bias. The cohort contains 13 individuals with both amp-
lified and non-amplified DNA samples. We observed a
1.5 fold increase in LOF variant burden in amplified
samples relative to non-amplified samples from the same
individuals (p = 0.0002 by paired Wilcoxon Signed Rank
test) (Fig. 2c), suggesting that WGA prior to sequencing
leads to an artificially inflated number of predicted LOF
variants.
To determine whether our choice not to realign BAM
files contributed to the observed WGA effect, we calcu-
lated LOF variant burden in our NewAlign and OldAlign
cohort using the same protocol. Realignment of the se-
quence data with BWA MEM increased the number of
LOF calls per individual but overall LOF burden was
highly correlated (Pearson R2 = 0.95) (Additional file 1:
Figure S7). WGA explained a significant amount of vari-
ance in LOF variant burden in both NewAlign and Old-
Align samples (Additional file 1: Figure S7). Thus we
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can conclude that realignment does not remove WGA
artifacts observed in our variant calling pipeline.
Characterizing WGA artifacts
Having demonstrated that WGA is associated with in-
creased LOF variant burden, we sought to characterize
WGA samples more deeply. We observe that WGA
samples have an excess of LOF indels while LOF SNV
burden appears unaffected, as expected from the
ANOVA results (Fig. 3a). Interestingly, WGA samples
had fewer variants overall, due more variable coverage
depth over the capture regions (Fig. 3b, Additional file 1:
Figure S8). Read depth was highly variable across genes
in WGA samples with an average depth of 165 X and
standard deviation of 140 X (Additional file 1: Figure
S8). As a consequence of this variable coverage, an aver-
age of 27 genes per sample had 0 coverage in WGA
samples (Fig. 3c).
As indel variant calls are the source of inflated LOF
variant burden in WGA samples, we next determined
which indels are enriched in WGA samples using a one-
way Fisher’s exact test. While it is impossible to distin-
guish errors from true indels definitively at this scale,
indels that are a found at a significantly higher frequency
in WGA samples relative to DNA samples are good can-
didates to be errors. The majority of WGA-enriched
Table 1 Variance in LOF SNV and indel burden explained by
technical covariates
Sum. Sq. Df F value P value % Var. Exp.
LOF SNV
C20X 1785.49 1 52.95 3.72e-13 0.0056
WGA 156.89 1 4.65 3.10e-02 0.0005
Center 716.08 2 10.61 2.48e-05 0.0023
BWA 79.59 5 0.47 7.97e-01 0.0003
RACE 30698.90 5 182.10 1.33e-184 0.0973
Residuals 281966.85 8363 0.8940
LOF Indel
C20X 52930.43 1 153.90 4.95e-35 0.0072
WGA 3744887.28 1 10888.62 0.0000 0.5080
Center 383585.43 2 557.65 4.53e-228 0.0520
BWA 169507.9 5 98.57 2.76e-101 0.0229
RACE 146904.86 5 85.42 7.59e-88 0.0199
Residuals 2876257.21 8363 0.3900
ANOVA results table
Sum. Sq. Sum of Squares; Df Degrees of Freedom; % Var. Exp. Percent variance
explained by each factor (factor Sum. Sq./total Sum. Sq.)
Fig. 2 WGA increases LOF variant burden. a LOF variant burden includes both SNV and indels. Red line indicates expected LOF burden from
ExAC (155). b Individual LOF variant burden in cancers with WGA samples plotted by WGA status..* =Wilcoxon rank sum test p < 0.05, ** =Wilcoxon
rank sum test p < 0.001. c Individual LOF variant burden in n = 13 samples that have both DNA and WGA samples available. ** =Wilcoxon paired rank
sum test p < 0.001
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indels are insertions, and the ratio of insertions to dele-
tions is skewed relative to non-enriched indel sites
(Fig. 3d). Further, 75% of WGA-enriched indels are LOF
relative to 60% of non-enriched indels (Fig. 3d). Upon
examining the size of the indels in base pairs, we noticed
that WGA-enriched insertions were larger than non-
enriched insertions and their size distribution deviated
from what is expected for coding indels (Fig. 3e,f ). The
length of indels in coding regions is frequently a mul-
tiple of three base pairs, due to natural selection acting
to maintain the reading frame [25]. WGA-enriched in-
sertions did not show this expected distribution, and
thus are more likely to be LOF frameshift indels. As pre-
viously reported, LOF variants are enriched for se-
quencing errors, supporting our hypothesis that the
excess LOF indels in WGA samples are technical arti-
facts [26].
We observe that the local sequence context surround-
ing WGA-enriched insertions has a higher GC content,
and that G and C insertions are twice as frequent in
WGA-enriched insertions than non-enriched insertions
(Additional file 1: Figure S9, Table S7). This observation
prompted us to look for homopolymer repeats in the
sequence surrounding WGA-enriched indels. WGA-
enriched indels occur in homopolymer repeats more fre-
quently than non-enriched indels (Table 2). Further,
indels that occur in homopolymer regions had an in-
creased allele frequency in WGA samples relative to
indels not in homopolymer regions, indicating that ho-
mopolymer indels are also more recurrent in WGA
Fig. 3 Characteristics of variant calls in WGA samples. a Individual LOF indel burden vs. individual LOF SNV burden. Color indicates WGA status.
b Total number of variant calls plotted by WGA status. c Number of genes with 0 read depth across 16,824 genes. d Fraction of insertions and
deletions in n = 5654 WGA-enriched and n = 34,880 non-enriched indels. Shading indicates LOF status. e Size in base pairs of WGA-enriched and
non-enriched indels. f Density plot showing distribution of insertion and deletion size for WGA-enriched and non-enriched indels. g Individual
burden of LOF indels for all indels, homopolymer + indels, indels 15 base pairs or longer, and other indels. Color indicates WGA status. Indel
burden calculated using GATK VQSR TS99 filter
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samples (Additional file 1: Table S8). We observe that
WGA-enriched indels are larger on average and are fre-
quently in homopolymer regions, but that these two
characteristics are mutually exclusive. To better resolve
the contribution of each of these indel types to WGA
technical artifacts, we define three distinct categories of
indels: homopolymer +, large, and all other indels
(Table 2). Calculating individual LOF indel burden for
each of these categories shows that the increased LOF
indel burden observed in WGA samples is due to an ex-
cess of LOF homopolymer + indels (Fig. 3g).
The pan-cancer cohort contains 492 individuals with
multiple germline WXS samples. Presumably, variants
that are not concordant between repeated samples on
the same individual are errors, and thus we used geno-
type discordance as a surrogate measure for variant call-
ing error. In addition to the 13 individuals with paired
normal WXS samples with and without amplification
(denoted WGA:DNA), 44 individuals have paired normal
WXS samples where both samples have been amplified
(denoted as WGA:WGA) and 435 are paired samples
without amplification (denoted DNA:DNA). We calcu-
lated genotype discordance between all repeated samples
for SNVs and indels separately and observed a stepwise
increase in discordance with amplification of one or
both samples. This effect was most apparent in indels,
with a median 59.9% indel discordance between repeated
WGA:WGA samples (Additional file 1: Figure S10). Cal-
culating indel discordance using the indel categories pre-
vious defined reveals that discordance between WGA
samples is highest for homopolymer + indels, lower for
large indels, and similar to DNA samples for other
indels (Additional file 1: Figure S10). This demonstrates
that WGA errors manifest as small indels in homopoly-
mer regions and large indels with no clear sequence
context bias.
WGA by multiple displacement amplification (MDA) is
known to create chimeric DNA rearrangements, which
manifest in the sequence data as reads with sequence from
noncontiguous portions of the reference genome (Add-
itional file 1: Figure S11) [27]. To determine if chimeric
reads were responsible for the large indels in WGA sam-
ples, we used BLAST to align the inserted and deleted se-
quences of large indels to the reference genome [28]. We
observe that 86% of WGA-enriched large insertion se-
quences have a BLAST match, whereas only 10% WGA-
enriched large deletions and non-enriched large indels
have a BLAST match (Additional file 1: Table S9). Further,
the BLAST matches for WGA-enriched insertions were
predominantly within 2 kb of the indel start position
which is in accordance with the mechanism of MDA
chimeric rearrangements (Additional file 1: Figure S12).
Thus, the large indels we observe in WGA samples can be
explained by known MDA artifacts (Additional file 1: Fig-
ure S11). Small indels in homopolymer regions may occur
by the same mechanism, as it has been shown that the
majority of MDA chimeric junctions occur in regions of
short complimentary sequence [27]. The small homopoly-
mer indel errors may also be due to known difficulties of
calling indels in homopolymer regions, which is exacer-
bated with amplification [29].
Filtering artifactual LOF variant calls
We next sought an appropriate filter to remove
artifactual LOF variant calls in WGA samples. As SNV
calls were largely robust to technical artifacts, we fo-
cused on filtering indels specifically (Additional file 1:
Figure S6). We used two strategies available from GATK:
1) Statistical model filtering using VQSR with increasing
stringency cutoffs (99, 95, 90%), and 2) Heuristic filtering
(Hardfilter) based on fixed thresholds (QD > 2, FS < 200,
ReadPosRankSum > -20), for a total of four filtering ap-
proaches [16]. The four filters varied in stringency,
resulting in a median individual LOF indel burden ran-
ging from 53 to 98 across methods (Fig. 4a and
Additional file 1: Figure S13). To assess the efficiency of
each filter to remove technical artifacts, we performed
an ANOVA analysis as described in Fig. 2 for each filter-
ing approach, including the initial filter (GATK VQSR
99) as a reference (Fig. 4b). VQSR 90 and VQSR 95 re-
duced technical artifacts to a similar degree, whereas
VQSR 99 and Hardfilters performed poorly (Additional
file 1: Figure S14A, Table S10).
Variant filtering is a balance between removing likely
false positive signal while retaining true positive signal.
Using VQSR 99 we observe an individual LOF variant bur-
den similar to that reported in the ExAC database, while
all other methods produce lower LOF burden than ex-
pected (Additional file 1: Figure S14A) [23]. Therefore,
while more stringent filtering approaches can reduce tech-
nical artifacts, they do so at the cost of losing likely true
positive indels. Without a way to manually validate a large
number of rare indel variant calls, it is impossible to exactly
measure false positives rates for our filter approaches.
Instead, we once again used the repeated samples in
our cohort to identify likely true positives (indels con-
cordant between repeated samples) and likely false posi-
tives (indels discordant between repeated samples). We
Table 2 Fraction of WGA-enriched and non-enriched indels in
three indel categories
% Other
Indels
% Homopolymer
Indels
% Large
Indels
WGA-enriched 47.78 27.13 25.07
Non-enriched 83.52 9.63 6.83
Homopolymer indels: indels with a 4 or more single base repeat directly
proximal to the indel; Large indels: indels with 15 or more inserted or deleted
bases. Other indels: all indels that don’t fit one of the previous criteria
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assessed filter quality using three measures: the fraction
of discordant indels removed by the filter, the fraction of
concordant indels removed by the filter, and the fraction
of indels overlapping the ExAC database. The stringency
of each filter was measured as the total number of LOF
indel sites and the median individual indel LOF burden
when each filter was applied (Table 3).
Consequences of technical artifacts on genetic associations
To determine how sensitive association results are to fil-
tering method, we tested for association between germ-
line LOF variant burden and cancer type using different
filtering approaches. We took an ‘one vs. rest’ approach
with our samples using all cancers except the cancer of
interest as a control. Thus, we tested for enrichment of
LOF germline variants in one cancer type as compared
to other cancers, which is different than other studies
that have used control cohorts [6]. Our rationale for
using this approach was to minimize heterogeneity that
would be introduced by including control samples col-
lected in different studies. We chose to highlight the re-
sults only from OV for two reasons. First, it is
established that BRCA1/2 germline variants are enriched
in OV so the OV—BRCA1/2 association can be used as
a positive control, and second virtually all OV samples
have been amplified and are confounded with WGA ar-
tifacts [6, 30, 31].
Quantile-quantile plots from logistic association tests
for three indel filter methods are shown in Fig. 5a. It
was immediately apparent that our initial filtering ap-
proach (VQSR 99) produced an excess of significant as-
sociations even above a strict Bonferroni multiple
hypothesis correction (Fig. 5b). True associations are
mixed with false associations due to WGA artifacts in
LOF indel calls. Increasing the stringency of indel filter-
ing reduced noise due to technical artifacts while retain-
ing a putative true positive BRCA1/2 association signal.
Stringent filtering removes noise at the cost of reducing
potential signal, as evidenced by the decreased number
of genes that can be tested for association. This inflation
in significant associations was only observed in cancers
containing WGA samples, and persisted, albeit to a far
lesser extent, even with the most stringent filter (Fig. 5b).
Supporting the idea that some of the associations in
WGA cancer types are false, only two of the significant
genes (BRCA1/2) in OV and none in LAML are genes
where germline variation is known to be associated with
cancer risk [32].
Fig. 4 A comparison of indel filtering strategies. a Individual LOF
indel burden for all indel filter methods in order of decreasing
stringency. b Percent of variation in individual LOF indel burden
explained by technical covariates for each filter method
Table 3 Metrics of filter stringency and efficacy
Filter LOF indel sites Median LOF
indel burden
Fraction discordant
indels removed
Fraction concordant
indels removed
Indel overlap
with ExAC
VQSR 90 6212 53 0.8667 0.4514 0.7079
VQSR 95 9177 59 0.8064 0.3760 0.6776
Hardfilter 24212 91 0.3600 0.0210 0.3527
VQSR 99 26134 98 0.2763 0.1100 0.5394
GATK VQSR 90 is the only filter capable of eliminating the significant association between WGA and LOF indel burden, however; it does so at the cost of over 75%
of all LOF indel sites (Additional file 1: Table S10). From this we can conclude that WGA artifactual indels closely resemble true indels, preventing VQSR from
selectively removing artifactual indels
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We observe that an unusually high fraction of signifi-
cantly associated genes were shared between LAML and
OV, with 69, 55, and 25% of significant genes shared for
VQSR filters TS99, TS95, and TS90, respectively
(Additional file 4: Table S11). Having demonstrated that
LOF indels occur at a high allele frequency in homopol-
ymer regions in WGA samples, we calculated the num-
ber of homopolymer regions in these shared genes. We
observe that shared genes have a higher G/C homopoly-
mer content compared to all genes tested (Additional
file 1: Figure S15). Further we see a stronger correlation
between LOF indel burden and homopolymer content in
WGA samples than in DNA samples (Additional file 1:
Table S12). Taken together, we can conclude that the
high fraction of shared genes between LAML and OV is
driven by high allele frequency LOF indels in homopoly-
mer regions. LOF indel calls are more prone to batch
effects than LOF SNVs, therefore we repeated the asso-
ciation test limiting to LOF SNVs only. While this re-
duces the excess number of significant associations, the
analysis was underpowered to detect the true positive
BRCA1/2—OV association (Additional file 1: Figure
S16). These results demonstrate that technical artifacts
can lead to spurious associations and highlight the diffi-
culty of correcting for artifacts in a pan-cancer analysis
when technical factors are highly correlated with the
phenotype being tested (Fig. 1).
Discussion
We identified sources of technical variation in LOF vari-
ant calls from TCGA germline WXS data. Overall SNV
calls were more robust to technical factors than indel
calls. We found the strongest association between ampli-
fication of DNA prior to sequencing and an excess of
LOF indel calls. Other factors tested were found to be
significantly associated with both LOF SNV and LOF
Indel burden, but explain little of the total variance in
LOF variant burden when appropriate filters are applied
(Table 1 and Fig. 4b). The factor explaining the most
technical variation in total LOF variant calls after
Fig. 5 Association testing between germline LOF variant burden and cancer type. a Quantile-quantile plots from logistic regression association
testing between germline LOF burden and ovarian cancer for three indel filter methods. n = number of genes tested. Red line indicates significant
cutoff and red points indicate associations significant p < 1.61 × 10-7. BRCA1/2 associations highlighted. b Number of significant cancer type - gene
associations in each cancer type for three indel filter methods. Color indicates cancer types with WGA samples
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filtering is capture efficiency (C20X). It is likely that poor
coverage over common capture regions, perhaps due to
the different capture technologies used, decreased the
ability to assign genotypes in some samples. Joint calling
distinguishes sites with insufficient coverage to make a
genotype call from those with adequate coverage for
calling a homozygous reference genotype. Therefore,
while C20X is a significant factor in the simple burden
analyses performed here, a more sophisticated burden
testing approach that can accommodate missing geno-
type values should mitigate this technical artifact.
Difficulty producing reliable variant calls in WGA ex-
ome samples has been previously reported [19, 33]. In-
accurate read alignment has been identified as a main
contributor to spurious calls in WGA samples. However,
even with an alignment protocol optimized for WGA
samples it is still estimated that 7% of variant calls in
WGA samples are artifactual [19]. Previous work com-
paring amplified and non-amplified DNA obtained from
the same biological sample report higher variant call dis-
cordance in indels compared to SNVs, similar to what
we observe [33]. These studies conclude that overall
concordance between amplified and non-amplified sam-
ples is satisfactory; however, neither examined the im-
pact of WGA on deleterious variants. Here we have
demonstrated that errors introduced by WGA manifest
as rare frameshift indels that are difficult to distinguish
from true rare deleterious variation. We further demon-
strated that the WGA indel errors we observe are in ac-
cordance with known errors and biases that occur due
to MDA, and provide a mechanism by which MDA
chimeric reads lead to erroneous indel calls (Additional
file 1: Figure S11). In addition to drawing attention to
batch effects in TCGA sequence data, our study also
provides valuable insight into potential pitfalls of calling
indels in sequence data generated from MDA.
Simultaneous to our investigation, the genomic data
commons (GDC) has called somatic mutations on TCGA
tumor sequence data using four different pipelines and
discovered an excess of insertion mutations in tumor sam-
ples with amplified DNA [34, 35]. This validates our find-
ings in the orthogonal process of somatic mutation
calling. Further, GDC only reports this observation for the
MuTect2 pipeline, which combines aspects of the original
MuTect algorithm and GATK’s ‘HaplotypeCaller’ [36]. As
WGA artifacts have thus far only been observed in
GATK-derived variant callers, it is possible that these arti-
facts are specific to the GATK pipeline. An alternate
method of variant calling could reduce or eliminate WGA
errors, but this issue is still problematic as GATK is one of
the most commonly used variant callers for large datasets
such as ExAC and gnomAD [23].
While joint calling is the approach recommended by
GATK, with the exception of one paper from our lab
exploring the impact of genetic background on joint
calling, to our knowledge there has not been a published
systematic comparison of joint calling vs. single sample
calling with GATK on a gold standard dataset to quan-
tify the advantages of joint calling [37]. GATK’s joint
calling approach is not without problems. Greater accur-
acy for the group as a whole comes at the cost of loss of
singleton variants from any given sample. Another com-
plicating factor unique to joint called samples are multi-
allelic sites, or sites where multiple alternate alleles are
found in the population genotyped. Relatively few sites
in our VCF were multi-allelic (3%, or 30,620 sites), but
these sites contain 4947 high-confidence LOF variants
(11% of all LOF variants), indicating the importance of
correct multi-allelic site parsing. Multi-allelic sites add-
itionally pose a problem when filtering reliable from unre-
liable variants. With current tools for filtering VCFs, it is
only possible to filter at the site level, meaning at multi-
allelic sites all alleles will either be included or excluded
by the filter. Further, in the version of GATK used for this
analysis (v3.5), quality annotations for a site are calculated
using all alternate reads without distinguishing between
alleles. Therefore it is possible for low quality alternate al-
leles to pass filter at multi-allelic sites if high quality alter-
nate alleles are present at the same site.
Conclusions
Our work shows that amplification of DNA prior to se-
quencing resulted in an excess of predicted damaging
indel variants. In our dataset, we find that using VQSR
TS90 can eliminate the significant association between
WGA and LOF indel burden, but it appears false associ-
ations persist in our association analyses (Fig. 5b,
Additional file 1: Table S10). Thus, we find removal of
WGA samples to be the only option to fully eliminate
batch effects in our dataset. It is possible WGA indel ar-
tifacts could be eliminated in WGA samples using a dif-
ferent variant calling approach perhaps sensitive to
MDA induced errors. The GDC has worked to optimize
MuTect2 parameters for WGA samples, and their
methods could potentially be applied to germline variant
calling [34]. We suggest that variant calling in these
samples should be handled with extra care.
TCGA is often thought of as a single dataset, but due
to differences in sample collection and processing across
the participating sites, should be thought of as a collec-
tion of studies. While we focused on the germline WXS
sequence data, it is likely that batch effects are present
in other data types. This has been recognized by the
Pan-Cancer TCGA effort, although it is less often ac-
knowledged in papers published on one or few cancer
types [10]. There is heterogeneity even within cancer
types in terms of sample preparation, such as in COAD
and READ where roughly a third of germline WXS
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samples were prepared using WGA. Batch effects
present in TCGA data can potentially confound even
single cancer type analyses if not properly addressed. In
terms of pan-cancer analysis, the correlation between
certain technical factors and cancer types confounds
analyses that use cancer type as the phenotype of inter-
est, as we demonstrated in Fig. 5. We note that since the
initiation of our analysis, the raw TCGA sequence data
have moved to the GDC [35]. The GDC has realigned
the sequence to the current reference genome (GRCh38
.d1.vd1) using a standardized pipeline to harmonize the
BAM file. Although this will eliminate one source of
variation (BWA version), it only serves to remind re-
searchers how sensitive data analyses might be to non-
standardized data collection protocols, especially in the
context of the TCGA data, as our study makes clear.
Analyses of large, extant data sets will continue to grow
and impact biomedical research, with many in the com-
munity committed to pointing out the need for care in
interpreting the results and impact of those analyses [14,
38, 39].
Methods
Cohort
Approval for access to TCGA case sequence and clinical
data were obtained from the database of Genotypes and
Phenotypes (dbGaP). We selected a total of 9618 normal
tissue DNA samples with whole exome sequence data
(Additional file 1: Table S1). We limited analysis to sam-
ples sequenced with Illumina technology and aligned to
the GRCh37/hg19 reference genome.
Germline Variant Calling
Aligned sequence data for normal samples in BAM file
format and the accompanying metadata was downloaded
from CGhub [17]. Individual samples were matched with
the target regions for the exome capture kit used to gen-
erate the sequence data, and variant calling was limited
to these target regions +/- 100 bp. SNVs and small
indels were identified using the GATK v.3.5/v.3.4 best
practices pipeline and a joint calling approach [15, 16].
The GATK pipeline includes two preprocessing steps to
improve the quality of the BAM file. Local realignment
of reads is performed in regions containing indels, and
base quality scores are recalibrated to minimize known
sources of score bias. ‘HaplotypeCaller’ was run on indi-
vidual samples in gVCF output mode, producing an
intermediate single sample gVCF to be used for joint
genotyping. Running this pipeline on a single BAM from
CGhub took approximately 15 compute hours and pro-
duced a 100 MB gVCF. Individual gVCFs were com-
bined in groups of 100 and the final joint genotyping
step was performed by chromosome on all 9618 samples
as a single cohort. Following this joint genotyping step,
all future analysis was limited to the intersection of all
exome kit capture regions. The intersection of the kits
covered 27 MB and 97.7% of Gencode v19 exons
(Additional file 1: Table S2) [18]. GATK VQSR was run
separately for SNVs and indels. VQSR learns from vari-
ant quality annotations using variants overlapping with
vetted resources such as dbSNP and 1000 genomes as a
truth set. VQSR filters are defined by the percentage of
truth variants that pass filter, termed truth sensitivity
(TS). For the initial analysis, SNVs were filtered at VQSR
TS 99.5% and indels at VQSR TS 99.0%, as suggested by
GATK documentation.
PCA and Self-Report Ancestry Validation
PCA was performed jointly on the filtered pan-cancer
VCF and HapMap genotype data from 1184 individuals
using PLINK v1.90b3.29 [40, 41]. Multiallelic sites, rare
variants (<1% AF), and sites with missing values were
excluded from the pan-cancer VCF. A final variant set of
4376 SNPs was obtained by taking the union of the pan-
cancer and HapMap variant calls, requiring 100% geno-
typing rate across all samples. To assess accuracy of self-
report ancestry from TCGA clinical data, principle
component (PC) loadings of TCGA samples and Hap-
Map samples were compared. HapMap samples were
clustered on PC 1 and PC 2 using the R package ‘flexclust’
and K-means clustering with k = 4 to roughly approximate
the four major TCGA self-reported ancestry categories
(White, Asian, Black, and Hispanic) (Additional file 1:
Table S4) [42]. TCGA samples were assigned to one of
these four clusters using the predict function and PC 1
and PC 2 loadings (Additional file 1: Table S5). Comparing
self-reported ancestry to HapMap cluster membership
showed 4% of TCGA samples had inaccurate self-reported
ancestry (Additional file 3: Table S6).
Annotation and BAM metrics
Putative LOF variants, defined here as stop-gained, non-
sense, frameshift, and splice site disrupting, were identi-
fied using the LOFTEE plugin for VEP and Ensembl
release 85 [24]. LOFTEE assigns confidence to loss of
function annotations based on position of variant in the
transcript, proximity to canonical splice sites, and con-
servation of the putative LOF allele across primates. For
our analysis we used default LOFTEE filter setting and
only included high confidence predicted LOF variants. A
variant was called LOF if it received a high confidence
LOF prediction in any Ensembl transcript.
Predicted variant effects were obtained using Annovar
v.2014Jul14 [43]. Annovar returns a single prediction for
each variant position, collapsing across transcripts and
reporting the most damaging variant prediction.
Allele frequencies were obtained from ExAC v0.3.1
and used for comparison to our cohort. [23]
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We quantified capture efficiency in this analysis as the
percentage of capture target area covered by at least 20
X read depth (denoted C20X). Sequence depth informa-
tion was obtained on BAMs downloaded from CGhub
using GATK ‘DepthOfCoverage’ and the corresponding
exon capture bed file to define coverage intervals. Gene
level read depth information was obtained from a 5113
BAM files using GATK ‘DepthOfCoverage’ and a RefSeq
exon coordinate file obtained from UCSC’s table browser
[44, 45]. For the gene level depth analysis, files were
downloaded from GDC legacy archive to preserve the
original sequence alignment [35].
Realignment Comparison
To assess the effect of heterogeneous alignment proto-
cols on variant calls, we realigned the raw sequence data
for a subset of our cohort. We chose 345 samples to rep-
resent a large range of sample preparation variation
present in the TCGA BAM files. Reads were stripped
from the BAM to generate a FASTQ file using samtools
v.0.1.18 bam2fq [46]. The FASTQ was realigned to
GRCh37 using BWA MEM v.0.7.12 (with parameters -t
3 -p -M) and duplicates were marked using Picard
v.1.131 [47, 48]. From this point the realigned BAM file
was processed through the same GATK pipeline de-
scribed above to produce individual gVCFs. To directly
compare the effect of realignment, we generated a VCF
for the 345 realigned samples (NewAlign) and for the
same 345 samples processed without the realignment
step (OldAlign). We were unable to run GATK indel
VQSR on a cohort of this size, thus we filtered both
VCFs with GATK SNV VQSR TS 99.5 and GATK indel
hardfilters (settings QD > 2, FS < 200, ReadPosRank-
Sum > -20). We calculated discordance between align-
ment pipelines as the percent discordant variant calls: 1-
(intersection of variant calls/union of variant calls). Vari-
ant calls were matched by position and alternate base,
disregarding zygosity.
WGA Enriched Indels
Indel allele counts were obtained for n = 614 WGA and
n = 9004 DNA samples separately. For each indel site,
we obtained a contingency table of the number observed
alternate allele counts vs number reference allele counts
in DNA vs WGA samples. Reference allele counts were
calculated as (2 * the number of samples) - alternate al-
lele count. A one-way Fisher’s exact test was used to de-
fine indels with allele counts enriched in WGA samples.
A threshold of p < 0.063 was used to define WGA en-
richment. This cutoff corresponds to the p value of a
one-way Fisher’s exact test for a singleton present only
in WGA samples. Using this method we define n = 5654
WGA-enriched and n = 34,880 non-enriched indels.
Homopolymer Indel Analyses
To determine if indels occurred within homopolymer se-
quences, we obtained the GRCh37 reference sequence
+/- 10 base pairs from each indel start position. The
only indels considered for homopolymer analysis were
those that were single base insertions or deletions or
multi base insertions or deletions of the same base. All
indels used for homopolymer analysis were < 15 bp in
length. An indel was labeled as a homopolymer + indel if
a sequential repeat of the inserted/deleted base/s oc-
curred within +/- 1 bp of the indel start position. Using
this method we labeled every indel in the pan-cancer
VCF as homopolymer +/-. The GC content of the region
+/- 10 bp of each indel was additionally determined as
number G,C bases/total number of bases.
Homopolymer content by gene was determined using
RefSeq coding exon definitions and the GRCh37 refer-
ence sequence [45]. For this analysis a homopolymer re-
gion was defined as four or more sequential repeats of a
single base pair. For each gene, the sequence of all cod-
ing exon regions was scanned for homopolymer se-
quences. Sum totals of number of homopolymers of
each type (A,T,C,G) were obtained. G/C and A/T homo-
polymers were considered together by summing single
base homopolymer counts. To compare homopolymer
content across genes of different sizes, these counts were
divided by the total number of base pairs in the gene’s
coding region to obtain the homopolymer count per ex-
onic basepair.
Chimera Read Analysis
We define large indels as those with an inserted or de-
leted sequence > = 15 base pairs in length. We identify n
= 1418 WGA-enriched and n = 2301 non-enriched large
indels. The inserted or deleted sequence for each indel
was aligned to the GRCh37 reference genome using
ncbi-blast-2.6.0+ (with parameters -reward 1 -outfmt 6
-num_alignments 1 -max_hsps 3) [28]. For insertions,
the match with the highest predicted similarly was
retained. For deletions, the best match excluding the ac-
tual deleted reference sequence was retained. For all
indels with a BLAST hit, the distance between the start
position BLAST hit and the indel start position was de-
termined. Indels with BLAST hits > 10 kB away from the
indel start position were excluded from this analysis, as
MDA chimera artifacts act predominantly within a 10kB
proximal region [27].
Repeated Samples
A subset of individuals in our cohort have multiple
germline DNA WXS samples. This cohort of 9618 sam-
ples represents 9099 unique individuals; 1012 of the nor-
mal WXS samples were obtained from 492 individuals
(2–5 samples per individual). The repeated samples all
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represent germline DNA from the individual, but differ
in terms of sample preparation, sequencing, and pro-
cessing. Percent discordance between repeated samples
was calculated as described above. One sample (TCGA-
BH-A0BQ) was removed from future analysis due to a
high discordance between two high coverage DNA sam-
ples. We suspect a sample label mismatch. For associ-
ation testing, we selected one the sample with the
highest coverage that was not whole genome amplified,
leaving 9098 samples.
Indel Filter Methods
To assess different indel filtering methods, indels were
extracted from the raw pan-cancer VCF using GATK
‘SelectVariants’. Multialleleic sites containing both SNPs
and indels were included in the indel VCF. Four filter
methods were tested on the pan-cancer indel VCF:
GATK VQSR TS 90.0, TS 95.0, TS 99.0, and GATK
Hardfilter. GATK VQSR and Hardfilter filters were ap-
plied using the modules ‘ApplyRecalibration’ and ‘Var-
iantFiltration’ respectively (Hardfilter settings QD > 2,
FS < 200, ReadPosRankSum > -20). Indels were addition-
ally identified using Varscan v.2.3.9 (with parameters –p-
value 0.1 –strand-filter 1) on BAMs downloaded directly
from CGhub with no preprocessing [49]. Single sample
indel VCFs were generated using Varscan for all 9618
samples in our cohort.
Statistical Methods
To detect contribution of technical factors to LOF vari-
ant burden Type II ANOVA was performed using the R
package”car” [50]. To determine the percent variance ex-
plained by technical factors the sum of squared error for
each factor was divided by the total sum of squared
error. To create 95% confidence intervals for non-
normally distributed data, we used the R package “boot”
[51]. The mean for each of 1000 bootstrap samples was
calculated and a confidence interval was constructed
using the boot.ci function with type set to “basic”.
To detect association between germline gene LOF sta-
tus and cancer type, we used an ‘one vs. rest’ approach.
For each cancer type, a binary (‘dummy’) vector was cre-
ated indicating whether each individual had the given
cancer type (1) or another cancer type (0). For sex spe-
cific cancers, only individuals of the same gender were
compared. LOF variants with AF < 0.05 were binned by
individual by gene to generate on individual LOF variant
count for each gene. Genes were only included in our
analysis if at least two individuals in the cohort had
germline LOF variants in the gene. For each cancer type
and each gene we used a logistic regression to test asso-
ciation between germline LOF variant burden and can-
cer type. Our regression model took the form:
glm(cancer type indicator ~ variant burden + race + age).
To discover significant gene-cancer type associations we
obtained the p value of the β coefficient for the variant
burden term and used a Bonferroni cutoff of 1.61 X 10-7
to account for multiple testing (31 cancer types x
~10,000 genes).
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